webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

N-(2-(3,4-Difluorophenoxy)ethyl)-4-Formylbenzamide

  CAS No.: 1226403-39-9   Cat No.: BADC-00565 4.5  

Difluorophenoxy-functionalized aldehyde ADC linker designed for precise conjugation chemistry, enhancing payload attachment and controlled release in targeted antibody-drug conjugates.

N-(2-(3,4-Difluorophenoxy)ethyl)-4-Formylbenzamide

Structure of 1226403-39-9

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C16H13F2NO3
Molecular Weight
305.28
Shipping
Room temperature

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
IUPAC Name
N-[2-(3,4-difluorophenoxy)ethyl]-4-formylbenzamide
Canonical SMILES
C1=CC(=CC=C1C=O)C(=O)NCCOC2=CC(=C(C=C2)F)F
InChI
InChI=1S/C16H13F2NO3/c17-14-6-5-13(9-15(14)18)22-8-7-19-16(21)12-3-1-11(10-20)2-4-12/h1-6,9-10H,7-8H2,(H,19,21)
InChIKey
XPJJURIOQNKFLI-UHFFFAOYSA-N
Shipping
Room temperature

N-(2-(3,4-Difluorophenoxy)ethyl)-4-Formylbenzamide, often recognized in the field of medicinal chemistry, has emerged as a vital compound with potential therapeutic applications. Its unique chemical structure enables it to interact with various biological targets, making it a significant subject of study in the development of novel pharmaceuticals. The presence of difluorophenoxy and formylbenzamide groups in its structure imparts unique electronic properties that are pivotal for its biological activity. Researchers are closely investigating its potential as a lead compound in drug discovery projects focused on treating chronic diseases, including cancer and inflammatory disorders.

A major application of N-(2-(3,4-Difluorophenoxy)ethyl)-4-Formylbenzamide is in oncology, where its role as a potential anti-cancer agent is being explored. The compound's ability to inhibit specific cancer cell proliferation pathways presents a promising therapeutic strategy. Studies have shown that it may induce apoptosis in cancerous cells, reduce tumor growth, and enhance the effectiveness of existing chemotherapy drugs. This has led to its consideration as a candidate for combination therapy, aiming to improve patient outcomes while minimizing adverse effects associated with conventional cancer treatments.

In addition to its anti-cancer properties, N-(2-(3,4-Difluorophenoxy)ethyl)-4-Formylbenzamide shows promise in treating inflammatory diseases. Its unique structure allows it to modulate the activity of certain enzymes and receptors involved in inflammation. By inhibiting these pathways, the compound could potentially reduce the symptoms of diseases such as rheumatoid arthritis and inflammatory bowel disease. Researchers are conducting in vitro and in vivo studies to further understand its efficacy and safety profile, with the goal of developing more effective anti-inflammatory medications.

Furthermore, N-(2-(3,4-Difluorophenoxy)ethyl)-4-Formylbenzamide is being studied for its potential in neurodegenerative disease research. The compound's properties suggest it might protect neuronal cells from degenerative processes, providing a new approach to treating conditions like Alzheimer's and Parkinson's disease. Ongoing research aims to elucidate the mechanisms by which this compound can offer neuroprotection, ultimately leading to innovative therapies that can halt or reverse the progression of neurodegenerative diseases. This application highlights the versatility of the compound and its relevance in addressing various unmet medical needs.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: DNP-PEG4-NHS ester | Fmoc-L-Lys(Pentynoyl-DIM)-OH | 4-pentynoic acid succinimidyl ester | Bis(NHS)PEG9 | Sulfo-SIAB sodium | Sulfo-SIAB | NHS-PEG(5)-CO-OBzl | N-Methyl-N-[(3-methyldithio)-1-oxopropyl]-L-alanine | MAL-Tri-EG-Osu | 4-Formyl-N-(2-(2,3,6-Trimethylphenoxy)ethyl)benzamide | m-C-tri(CH2-PEG1-NHS ester)
Send Inquiry
Verification code
Inquiry Basket